Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

Replidyne Gets $50M Up Front Through Forest Collaboration

Feb. 14, 2006

By Jennifer Boggs

After First Product Approval, BioMimetic Seeks $50M IPO

Feb. 13, 2006

By Jennifer Boggs

Private Placement Adding $27M To VaxGen’s Anthrax Drug Work

Feb. 13, 2006

By Jennifer Boggs

Private Placement Adding $27M To VaxGen’s Anthrax Drug Work

Feb. 13, 2006

By Jennifer Boggs

After First Product Approval, BioMimetic Seeks $50M IPO

Feb. 13, 2006

By Jennifer Boggs

Inflabloc Adds Cancer Drugs Through Merger, Raises $6M

Feb. 10, 2006

By Jennifer Boggs

Inflabloc Adds Cancer Drugs Through Merger, Raises $6M

Feb. 10, 2006

By Jennifer Boggs

Immtech Prices $16M Public Offering; EpiCept Adds $11M

Feb. 9, 2006

By Jennifer Boggs

Immtech Prices $16M Public Offering; EpiCept Adds $11M

Feb. 9, 2006

By Jennifer Boggs

ARYx Series E Gets $30M To Fund Proof Of Concept

Feb. 8, 2006

By Jennifer Boggs

View All Articles by Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 14, 2025.
Australian researchers discover new compound to treat long COVID
BioWorld
Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for the debilitating condition in humans....
Biopharma exempt from US reciprocal tariffs, but not untouched
BioWorld
At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
FDA wants a shift away from animal testing
BioWorld MedTech
In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower...